ArteraAI and the American Cancer Society formed a collaboration focused on the development of AI-driven cancer therapy personalization.
Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.
